The market has been high on Brainstorm Cell Therapeutics Inc (BCLI) stock recently. BCLI gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObservers Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

Brainstorm Cell Therapeutics Inc (BCLI) stock is up 7.94% while the S&P 500 is lower by -0.12% as of 12:02 PM on Tuesday, Jan 26. BCLI has risen $0.46 from the previous closing price of $5.79 on volume of 3,810,664 shares. Over the past year the S&P 500 is up 18.72% while BCLI has risen 49.88%. BCLI lost -$1.02 per share in the over the last 12 months.

To screen for more stocks like Brainstorm Cell Therapeutics Inc click here.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Click Here to get the full Stock Score Report on Brainstorm Cell Therapeutics Inc (BCLI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

Read the original here:
Should You Buy Brainstorm Cell Therapeutics Inc (BCLI) Stock on Tuesday? - InvestorsObserver